Osteocalcin modulates parathyroid cell function in human parathyroid tumors.

Chiara Verdelli, Giulia Stefania Tavanti, Irene Forno, Valentina Vaira, Riccardo Maggiore, Leonardo Vicentini, Paolo Dalino Ciaramella, Francesca Perticone, Giovanni Lombardi, Sabrina Corbetta

Journal: Frontiers in endocrinology 2023;14():1129930

PMID: 37065733

Abstract

[{"label":"INTRODUCTION","text":"The bone matrix protein osteocalcin (OC), secreted by osteoblasts, displays endocrine effects. We tested the hypothesis that OC modulates parathyroid tumor cell function."},{"label":"METHODS","text":"Primary cell cultures derived from parathyroid adenomas (PAds) and HEK293 cells transiently transfected with the putative OC receptor GPRC6A or the calcium sensing receptor (CASR) were used as experimental models to investigate \u03b3-carboxylated OC (GlaOC) or uncarboxylated OC (GluOC) modulation of intracellular signaling."},{"label":"RESULTS","text":"In primary cell cultures derived from PAds, incubation with GlaOC or GluOC modulated intracellular signaling, inhibiting pERK\/ERK and increasing active \u03b2-catenin levels. GlaOC increased the expression of and , and reduced and . GluOC stimulated transcription of , and inhibited expression. Moreover, GlaOC and GluOC reduced staurosporin-induced caspase 3\/7 activity. The putative OC receptor GPRC6A was detected in normal and tumor parathyroids at membrane or cytoplasmic level in cells scattered throughout the parenchyma. In PAds, the membrane expression levels of GPRC6A and its closest homolog CASR positively correlated; GPRC6A protein levels positively correlated with circulating ionized and total calcium, and PTH levels of the patients harboring the analyzed PAds. Using HEK293A transiently transfected with either GPRC6A or CASR, and PAds-derived cells silenced for , we showed that GlaOC and GluOC modulated pERK\/ERK and active \u03b2-catenin mainly through CASR activation."},{"label":"CONCLUSION","text":"Parathyroid gland emerges as a novel target of the bone secreted hormone osteocalcin, which may modulate tumor parathyroid CASR sensitivity and parathyroid cell apoptosis."},{"copyright":"Copyright \u00a9 2023 Verdelli, Tavanti, Forno, Vaira, Maggiore, Vicentini, Dalino Ciaramella, Perticone, Lombardi and Corbetta."}]
Address: Laboratory of Experimental Endocrinology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.; Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.; Division of Pathology, Fondazione IRCCS Ca` Granda Ospedale Maggiore Policlinico, Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.; Endocrine Surgery, IRCCS Ospedale San Raffaele, Milan, Italy.; Endocrine Surgery, IRCCS Istituto Auxologico, Milan, Italy.; Endocrinology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.; Endocrinology Unit, IRCCS Ospedale San Raffaele, Milan, Italy.; Laboratory of Experimental Biochemistry and Molecular Biology, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.; Department of Athletics, Strenght and Conditioning, Poznań University of Physical Education, Poznań, Poland.; Endocrinology and Diabetology Service, IRCCS Istituto Ortopedico Galeazzi, Milan, Italy.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.